NEW YORK – Fresh off of a $270 million Series C financing round, multi-omics liquid biopsy firm Freenome said that it has expanded its ongoing colorectal cancer early detection trial, PREEMPT, by opening recruitment to any US individual meeting the trial criteria, regardless of their location.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.